key: cord-1030040-tuy1wm8l
authors: Dublin, S; Walker, R; Floyd, J S; Shortreed, S M; Fuller, S; Albertson-Junkans, L; Harrington, L B; Greenwood-Hickman, M A; Green, B B; Psaty, B M
title: Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study
date: 2020-10-13
journal: Am J Hypertens
DOI: 10.1093/ajh/hpaa168
sha: 355b6cca54ff08b46917c3b2590cec6cfcb434c6
doc_id: 1030040
cord_uid: tuy1wm8l

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of COVID-19 infection or affect disease severity. Prior studies have not examined the association of medication dose with risks. METHODS: This retrospective cohort study included people aged ≥18 years enrolled in a US integrated healthcare system for at least 4 months as of 2/29/2020. Current ACEI and ARB use was identified from pharmacy data, and the estimated daily dose was calculated and standardized across medications. COVID-19 infections and hospitalizations were identified through 6/14/2020 from laboratory and hospitalization data. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals, adjusting for race/ethnicity, obesity and other covariates. RESULTS: Among 322,044 individuals, 826 developed COVID-19 infection. Among people using ACEI/ARBs, 204/56,105 developed COVID-19 (3.6 per 1000 individuals) compared with 622/265,939 without ACEI/ARB use (2.3 per 1000), yielding an adjusted OR of 0.91 (95% CI 0.74-1.12). For use of < 1 defined daily dose vs. nonuse, the adjusted OR for infection was 0.92 (95% CI 0.66-1.28); for 1 to < 2 defined daily doses, 0.89 (95% CI 0.66-1.19); and for ≥2 defined daily doses, 0.92 (95% CI 0.72-1.18). The OR was similar for ACEIs and ARBs and in subgroups by age and sex. 26% of people with COVID-19 infection were hospitalized; the adjusted OR for hospitalization in relation to ACEI/ARB use was 0.98 (95% CI 0.63-1.54), and there was no association with dose. CONCLUSIONS: These findings support current recommendations that individuals on these medications continue their use.

A c c e p t e d M a n u s c r i p t Introduction Use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), prescribed for nearly 25% of US adults, 1 may be a risk factor for coronavirus disease 2019 because these drugs increase the expression of angiotensin converting enzyme 2 (ACE2), 2 the receptor by which the SARS-CoV-2 coronavirus enters epithelial cells. 3 Concern about whether inhibitors of the reninangiotensin-aldosterone system (RAAS) may increase susceptibility to COVID-19 has been so pronounced that professional societies issued advisories urging patients not to discontinue them and calling for more evidence. 4 On the other hand, experimental evidence suggests that upregulation of ACE2 may protect against lung injury caused by severe coronavirus infection. 5 Among hospitalized patients with COVID-19 and hypertension, those on ACEI/ARBs had lower levels of highsensitivity C-reactive protein and procalcitonin. 6 Most observational studies have focused on people hospitalized for COVID-19, examining whether ACEI/ARB use is associated with worse clinical outcomes. [6] [7] [8] [9] While this sampling design addresses important questions, it selects for patients who are already infected and whose disease has become severe enough to require hospitalization, Such studies cannot shed light on the natural history of infection prior to hospitalization or whether the use of RAAS inhibitors may increase susceptibility to Three studies have examined the risk of infection in relation to RAAS use among people from well-characterized populations with information about prior medication exposures and health conditions. [10] [11] [12] These studies, set in Italy, 10 Spain 11 and Denmark, 12 found no overall association between RAAS inhibitor use and COVID-19 infection. Testing patterns and case fatality rates may vary widely between countries. 13 No true populationbased study has yet been conducted in the US, which has a very different health care system and more racially diverse population than these European countries. While rigorous, these A c c e p t e d M a n u s c r i p t 5 studies lacked information about smoking status, obesity and race/ethnicity, which may be important confounders, [14] [15] [16] and their COVID cases were disproportionately weighted towards hospitalized caseslacking cases from the milder end of the spectrum. Finally, no study has yet examined the relationship between ACEI/ARB dose and risk of COVID-19 infection or severe disease.

In a population-based setting with rich electronic health data, we evaluated the associations of ACEI and ARB use including medication dose with the risk of COVID-19

infection and, as a marker of severity, with hospitalization.

We conducted a retrospective cohort study within Kaiser Permanente Washington (KPWA), an integrated health care system in Washington State. Members within the integrated group practice (IGP) receive all or nearly all care from KPWA. Because KPWA does not own or operate hospitals, when members need hospitalization they are cared for at contracted hospitals, which submit claims to KPWA for reimbursement. Because reimbursement depends on these records, data about these hospitalizations tend to be very accurate. The population eligible for these analyses was IGP members who were aged ≥ 18 years and enrolled in KPWA in February 2020 (the month before COVID-19 testing began at KPWA). To be included, members had to have at least 4 months of prior enrollment as of 2/29/2020 and additional enrollment beyond that date. The sample size was determined by the number of eligible people. Individuals were followed for study outcomes through 6/14/2020. Study procedures were approved by the KPWHRI Institutional Review Board with a waiver of consent.

We used electronic pharmacy data to define exposure to RAAS inhibitors. Pharmacy data come from KPWA-owned pharmacies and in addition include medications dispensed at outside pharmacies (via claims data). Data were available in near-real-time, including A c c e p t e d M a n u s c r i p t 6 dispensings up through the day prior to the data pull. Data include a member identification number, date of the fill, medication name and strength, number of pills dispensed, and estimated days' supply. "Current use" was defined as having a dispensed medication with a supply sufficient to last until 2/29/2020 or later, assuming 80% adherence. To estimate the daily dose, we multiplied the number of pills dispensed by pill strength and divided by the estimated days' supply for the dispensing. We then standardized these daily doses across medications by dividing by the World Health Organization's Defined Daily Dose for each medication (e.g., 10 mg of lisinopril). 17 We defined COVID-19 infection as having a positive COVID-19 reversetranscriptase polymerase chain reaction (PCR) test or a hospitalization with a COVID-19 diagnosis code (patients admitted to contracted hospitals for severe illness would not necessarily have had prior COVID-19 testing at KPWA). In addition to laboratory test results from KPWA labs, we were able to access laboratory results from other healthcare systems that use the Epic medical record (available via CareEverywhere). Throughout the study period, KPWA followed Washington State testing guidelines regarding indications for testing. For much of this time, the guidelines recommended testing only individuals with severe illness and symptomatic patients with high-risk exposures or health conditions. 18 In some instances, a KPWA member had a hospitalization with a COVID-19 diagnosis but we could not identify a positive COVID test from a KPWA laboratory. To assess whether these apparent COVID-19 hospitalizations represented true cases, we reviewed medical records for 20 patients hospitalized with a COVID-19 diagnosis who did not have a positive COVID-19 PCR test within KPWA.

In defining our outcomes, we chose to include individuals hospitalized with a COVID-19 diagnosis but no positive laboratory test accessible to us as having both COVID-19 infection and hospitalization. Our rationale was that hospitalization for COVID-19 is a A c c e p t e d M a n u s c r i p t 7 serious and important outcome and our priority was to avoid missing potential cases. This is especially important because limited testing in the US in the early days of the pandemic resulted in many people not being tested until their symptoms became severe enough to warrant hospitalization.

We identified covariates from KPWA electronic health data. Demographic characteristics included age, sex, and self-reported race/ethnicity. We ascertained chronic medical conditions using diagnosis codes from inpatient and ambulatory visits; a condition was considered to be present if an individual had one or more codes for that condition in any We carried out descriptive analyses examining characteristics of the cohort stratified by exposure status (i.e., use of ACEI/ARBs). We used counts and proportions to describe categorical variables and means and standard deviations for continuous variables, and we calculated standardized mean differences 19, 20 to examine covariate balance between groups.

Next, within the entire cohort, we used logistic regression to estimate the odds of COVID-19 infection associated with RAAS inhibitor use with adjustment for age (<45, 45-64, 65+ years), sex, race/ethnicity (categorized as non-Hispanic white, non-Hispanic Black, non-Hispanic Asian, non-Hispanic mixed or other race, or Hispanic), diabetes, hypertension, heart failure (HF), prior myocardial infarction (MI), asthma, chronic obstructive pulmonary disease (COPD), current tobacco use, renal disease, malignancy, Charlson comorbidity score 21 (categorized as 0, 1, 2+), BMI (categorized as underweight, <18.5 kg/m 2 ; normal weight, A c c e p t e d M a n u s c r i p t 8 18.5-24.9 kg/m 2 ; overweight, 25-29.9 kg/m 2 ; obese, 30-34.9 kg/m 2 ; and severely obese, ≥ 35 kg/m 2 ), and use of insulin, loop diuretics, and prednisone. Among those with COVID-19 infection, we used logistic regression to estimate the odds of hospitalization associated with RAAS inhibitor use with adjustment for a reduced set of covariates. To account for missing data on race/ethnicity (13%) and BMI (27%), we used multiple imputation by chained equations 22 to generate 25 datasets with missing information imputed. Logistic regression models were estimated using these datasets and results were pooled following Rubin's rules. 23 We conducted analyses examining the association between ACEI/ARB daily dose and risk of infection or hospitalization. The referent category was no use of ACEI/ARBs. The standardized daily dose was grouped as < 1, 1 to <2, and ≥ 2 defined daily doses (DDDs) per day.

for ACEI and ARB use separately and in subgroups by sex and age (< 65 or ≥ 65 years). For the latter, we included interaction terms between each factor and RAAS inhibitor use in the models and tested significance with a Wald test of the interaction term. In sensitivity analyses, we examined other antihypertensive medications as "control exposures" to evaluate whether associations were specific to RAAS inhibitors. Because many chronic health conditions are indications for both COVID-19 testing and RAAS inhibitor use, we repeated our primary analyses of COVID-19 infection limited to individuals who underwent testing and separately, to those with an indication for RAAS inhibitors (hypertension, diabetes, HF or prior MI). For risk of infection, we conducted additional sensitivity analyses restricted to individuals taking at least one antihypertensive medication, adjusted for the number of medications.

A c c e p t e d M a n u s c r i p t 9 Analyses were conducted using R version 3.5.3 (Vienna, Austria) including the mice package (version 3.8.0). Figure 1 shows the selection of the study sample. There were 322,044 eligible individuals; their mean age was 51 years, 74% were non-Hispanic white and 46% were male. 56,105 (17%) were current users of ACEIs or ARBs. Lisinopril accounted for 96% of ACEI fills and losartan 97% of ARB fills. Individuals using ACEI/ARBs were older than nonusers, more likely to be obese, and more likely to have many chronic conditions, consistent with indications for RAAS inhibitor use (Table 1) . Among ACEI/ARB users, 21% had a low daily dose (< 1 DDD per day), 32% had a medium dose (1 to < 2 DDD/day) and 47% a high dose (≥ 2 DDD per day).

Among 18,252 people tested for COVID-19 between 2/29/2020 and 6/14/2020, 796 There was no association between the daily dose of ACEI/ARB and risk of infection ( Figure   2 ); the adjusted OR for people taking a low dose (< 1 DDD per day) compared to nonusers A c c e p t e d M a n u s c r i p t Figure 3) ; for people taking a high daily dose, the adjusted OR for hospitalization was 0.92 (95% CI 0.53-1.62) compared to nonuse.

In sensitivity analyses, the adjusted OR for COVID-19 infection was similar for ACEI and ARB users and in subgroups by age and sex ( Figure 2 ). Risk estimates for ACEIs and ARBs were slightly higher than for thiazides, beta-blockers or calcium channel blockers ( Figure 2 ). Findings changed little after restricting to individuals with an indication for RAAS inhibitor therapy, those tested for COVID-19, or those treated with antihypertensive medications. In sensitivity analyses examining COVID-19 hospitalization (Figure 3) , the adjusted OR for ACEIs was 0.81 (95% CI 0.50-1.31) and for ARBs, 1.29 (0.75-2.24). ACEI/ARB use was not associated with risk of COVID hospitalization for people under age 65 or age 65+. Results appeared modestly different by sex, with an adjusted OR for ACEI/ARB use that was lower in women than in men, but this difference was not statistically significant (p = 0.16).

A c c e p t e d M a n u s c r i p t 11

In this population-based cohort study set within a US healthcare system, there was no significant association between use of RAAS inhibitors and the risk of COVID-19 infection or hospitalization, including no association of these outcomes with ACEI/ARB daily dose. This is the first study to our knowledge that has examined the association of medication dose with COVID-19 outcomes.

Most published studies have focused on the risk of complications among hospitalized patients. [6] [7] [8] [9] Our finding for infection risk is consistent with several other population-based studies, 10-12 including a case-control study from Italy where the adjusted OR for infection in relation to ACEI/ARB use was 0.95 (95% CI 0.86-1.05) 10 and a study from Denmark where the adjusted OR was 1.05 (95% CI 0.80-1.36). 12 Examining this question in the US is important because of differences in the clinical context, COVID-19 testing practices and case fatality rates, 13 and the distribution of race/ethnicity in the population.

A recent systematic review assessed the association between RAAS inhibitor use and COVID-19 infection and outcomes; 24 they concluded that there is "moderate-certainty evidence" from 3 studies that ACEI/ARB use does not increase infection risk and stronger evidence that ACEI/ARB use does not increase the risk of severe outcomes. They noted limitations of prior studies including that many were small or did not adjust for important confounders, and that for some of the smaller studies, it was unclear how prior RAAS inhibitor use was ascertained. The 3 large population-based studies [10] [11] [12] of this question (one of which was included in the systematic review 10 ) were all set in Europe. They have many strengths and offer important evidence, but gaps still remain. When identifying COVID-19

infections, one study focused solely on hospitalized cases 11 and a second ascertained only patients diagnosed in hospitals or hospital-based clinics. 12 The cases identified thus represent more severe cases on the disease spectrum, and there remains a need for studies including A c c e p t e d M a n u s c r i p t 12 cases with milder disease diagnosed in the ambulatory setting. The definition of exposure varied across studies, with potential for misclassification, and none of these studies included information about ACEI or ARB daily dose.

We also observed a 4-fold higher risk of infection among Black people and a 2.7-fold risk of infection for Hispanics compared to non-Hispanic whites. These findings are consistent with prior studies that reported higher risk of hospitalization due to COVID-19 among Black 14 or Hispanic 14, 16 people. In addition, we observed a significantly lower risk of infection among current smokers (RR 0.56, 95% CI 0.39-0.80). This finding is consistent with a number of prior studies including a meta-analysis of 17 studies that reported a combined RR of 0.74, with 95% credible interval of 0.58-0.93, for the association between current smoking and COVID-19 infection. 25 The potential biologic mechanism for an association between smoking and lower risk of COVID-19 infection is unclear. One study reported that nicotine downregulates expression of the ACE2 receptor, by which SARS-CoV-2 enters epithelial cells. 26 The reported association could also be due to bias, including bias due to selective testing for COVID-19. Respiratory symptoms (more common in current smokers) are a common indication for testing, and smokers are more likely to have chronic conditions such as chronic lung disease which early in the pandemic were often a prerequisite for testing. At the same time, smokers are at higher risk for many viral and bacterial respiratory infections, which could make them more likely than non-smokers to have an illness other than COVID-19 as the cause of their symptoms. These factors could contribute to an apparent "protective effect" of smoking in the absence of a causal association.

This study provides additional evidence that RAAS inhibitors do not increase the risk of SARS-CoV-2 infection. Strengths include the ability to examine the risk of COVID-19 infection including both outpatient and hospitalized cases arising in a well-defined population with extensive electronic health data and complete capture of clinical events. We were able to A c c e p t e d M a n u s c r i p t 13 estimate people's daily dose of ACEI/ARBs and to adjust for characteristics typically missing from large healthcare databases such as smoking, BMI and race/ethnicity, characteristics which seem to have strong associations with risk of COVID-19 infection or more severe disease. [14] [15] [16] Longitudinal data available for patients for years prior to the start of follow up improve the accuracy of ascertaining chronic illnesses and prior medication use.

Limitations of observational studies such as this one include measurement error, selection bias, and residual confounding. Because KPWA testing practices followed state guidelines, we lack information about milder cases or those in low-risk populations, for whom COVID-19 testing was not considered to be indicated throughout most of the study period. We could be missing hospitalizations for people who tested positive during follow-up and were hospitalized after the end of our follow-up period. In defining our outcomes, we included as having COVID-19 infection some individuals hospitalized with a diagnosis of COVID-19 for whom we could not identify a positive laboratory test result. This could have led to bias because these individuals would not have been identified as infected had they not experienced a hospitalization. At the same time, if we had defined them as not experiencing COVID-19 infection, this choice could have led to misclassification of outcome status. There is no clear right answer in this situation. We believe that our approach is unlikely to have caused substantial bias, for several reasons. First, the number of individuals involved (30) is small compared to the total number with COVID-19 infection or hospitalization in our study.

Second, we do not expect an association between ACEI/ARB use and this method of case ascertainment. Third, our results changed little in sensitivity analyses that could have shed light on any resulting bias, including analyses limited to people with a COVID-19 test and those with a chronic illness that is both an indication for ACEI/ARB use and a risk factor for COVID-19 testing and/or hospitalization. A c c e p t e d M a n u s c r i p t 23 

Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

A pneumonia outbreak associated with a new coronavirus of probable bat origin

HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study

Association of Renin-Angiotensin System

Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for

COVID-19) Infection in Wuhan, China

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust

Aldosterone System Blockers and the Risk of Covid-19

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States

Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

Multiple imputation of discrete and continuous data by fully conditional specification

Multiple imputation for nonresponse in surveys

Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or

Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults. A Living Systematic Review

The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses

Nicotine and the reninangiotensin system

Hispanic White Ref. ‡ Ref. ‡ Non

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t details. ¶ Coefficients for diabetes, heart failure, prior myocardial infarction, malignancy and renal disease should be interpreted with caution as these variables are also included in the Charlson comorbidity score.